The Centers for Disease Control and Prevention said Friday that Moderna Inc.’s MRNA
The COVID-19 vaccine causes an allergic reaction in a small percentage of people, similar to the agency’s findings on the coronavirus vaccine developed by BioNTech SE BNTX,
and Pfizer Inc. PFE,
Moderna’s stock rose 1.6% in premarket trading Monday. According to the CDC report, there were 10 cases of anaphylaxis among the approximately 4 million doses administered between December 21 and January 10. Both vaccines are mRNA-based vaccines, with similar efficacy rates in clinical studies. These are the only two COVID-19 vaccines authorized in the US so far during the pandemic. The CDC has previously recommended that health care providers prepare for the possibility of anaphylaxis in some people who are being vaccinated. Moderna’s stock is up 520.3% in the last 12 months, while the S&P 500 SPX,
is up 15.6%.